Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Outcomes for patients with acute myeloid leukemia (AML) have improved due to advances in therapeutic approaches in combination with improvements in supportive care. However, relapse remains a significant clinical challenge and research has focused on maintenance strategies to extend remission and overall survival in patients with AML.1
Induction therapy on post-transplant outcomes
Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
Novel transplant strategies, and reducing the risk of relapse
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Maintenance therapy: agents under investigation and future outlooks
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Ongoing clinical trials and targeted therapies
VENTOGRAFT trial: AZA, VEN, and DLI in patients
with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau, MD, PhD
University Hospital of Nice, Nice, France
Gilteritinib as post-transplant maintenance therapy
in FLT3-ITD AML
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Relapse in AML
Treatment approaches for patients with R/R AML and the importance of preventing relapse
Alessandro Isidori, MD, PhD
Marche Nord Hospital, Pesaro, Italy
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD
King’s College Hospital NHS Foundation Trust, London, UK
Reference:
1. Reville, P.K. and Kadia, T.M. Maintenance therapy in AML. Frontiers in Oncology 2021;10:619085. doi:10.3389/fonc.2020.619085.
5:18
Glossary
AML, acute myeloid leukemia
This educational activity has received independent medical education support from Bristol Myers Squibb. This supporter has no influence over the production of the content.
